STOCK TITAN

Merus to Present at Upcoming Investor Conferences

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in multispecific antibodies, has announced its participation in two upcoming investor conferences. Bill Lundberg, M.D., President and CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12 at 9:30 a.m. ET and at the Stifel 2024 Healthcare Conference on Monday, November 18 at 3:00 p.m. ET. Both presentations will be available via webcast on the company's website's Investors page, with archived versions accessible for a time afterward.

Loading...
Loading translation...
Argus Session date unavailable
+2.58% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was +2.58%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

  • Guggenheim Securities Healthcare Innovation Conference (fireside chat): Tuesday, November 12 at 9:30 a.m. ET
  • Stifel 2024 Healthcare Conference (fireside chat): Monday, November 18 at 3:00 p.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Merus (MRUS) presenting at the Guggenheim Securities Healthcare Innovation Conference?

Merus (MRUS) will present at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12 at 9:30 a.m. ET.

When is Merus (MRUS) presenting at the Stifel 2024 Healthcare Conference?

Merus (MRUS) will present at the Stifel 2024 Healthcare Conference on Monday, November 18 at 3:00 p.m. ET.

Where can investors watch Merus (MRUS) investor conference presentations?

The presentations will be available via webcast on the Investors page of Merus' website, with archived versions accessible for a time after the events.

Who will represent Merus (MRUS) at the upcoming investor conferences?

Bill Lundberg, M.D., President and CEO of Merus, will represent the company at both investor conferences.

Keep reading